In this webinar, experts discuss problems common to the development, testing and manufacturing of intranasal drug products, their potential causes, and possible consequences.
Summary: This article explores the key factors pharmaceutical companies should consider when selecting a CDMO and evaluating its multi-product facility capable of handling HPAPIs to de-risk their programs and bring their products to patients safely.
Summary: Discover how Catalent, a specialized CDMO, accelerates time to market for inhalation innovators with end-to-end solutions.
Summary: In this article, experts discuss how the intranasal route offers advantages like faster absorption and minimal product degradation, but also the complex issues to consider when designing a device that will ensure the efficacy of a particular formulation.
Summary: This article, originally published in Inhalation Magazine, discusses process & applications considerations for the spray drying of inhaled powders, considerations for formulating biologics as respirable powders and inhalation for non-respiratory indications.
Summary: In this article experts shared their insights on developing intranasal products and scaling them for commercial supply.
